OncoMatch/Clinical Trials/NCT05797077
Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA
Is NCT05797077 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FOLFOX chemotherapy regimen and Capecitabine for colorectal cancer.
Treatment: FOLFOX chemotherapy regimen · Capecitabine — The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM) patients with positive ctDNA after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — R0 resection or ablation with R0 effect
have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect)
Cannot have received: investigational drug
Patients who have received other tumor-related investigational drug treatments
Lab requirements
Kidney function
no severe kidney dysfunction
Liver function
no severe liver dysfunction
Cardiac function
no cardiorespiratory dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify